clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Endometriosis D004715 29 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Diarrhea D003967 32 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Fever D005334 35 associated lipids
Heart Failure D006333 36 associated lipids
Lung Diseases D008171 37 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Soepandi P et al. The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections. 1998 Respirology pmid:9692520
Elliott RL et al. Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. 1998 J. Med. Chem. pmid:9572890
Griesgraber G et al. Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues. 1998 J. Med. Chem. pmid:9572891
Sakurai N et al. Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents. 1998 Bioorg. Med. Chem. Lett. pmid:9873510
Komori T et al. Effect of clarithromycin on alpha1-acid glycoprotein levels in normal and diabetic rats. 1998 Res. Commun. Mol. Pathol. Pharmacol. pmid:9874281
Matteelli A et al. Long term treatment with clarithromycin for cryptosporidiosis and emergence of drug resistant disseminated infection due to Mycobacterium avium: case report. 1998 J Chemother pmid:9876056
Vorbach H et al. Endothelial cell compatibility of clarithromycin for intravenous use. 1998 Clin. Biochem. pmid:9876898
Miglioli PA et al. Antibacterial activity of human pleural fluid: alone and in combination with antibiotics. 1998 Int. J. Antimicrob. Agents pmid:9916908
Garrido A et al. [Eradication of Helicobacter pylori by triple therapy in ulcerous patients: the role of endoscopy and antibiotic sensitivity]. 1998 Enferm. Infecc. Microbiol. Clin. pmid:9918994
Matsushima T and Miyashita N [Basic and clinical study of Chlamydia pneumoniae infections]. 1998 Nippon Naika Gakkai Zasshi pmid:9922675
Stefansson P et al. Cefuroxime axetil versus clarithromycin in the treatment of acute maxillary sinusitis. 1998 Rhinology pmid:9923060
Pazzi P et al. Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. 1998 Aliment. Pharmacol. Ther. pmid:9726385
Harris AW et al. Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. 1998 Aliment. Pharmacol. Ther. pmid:9726387
Bermudez LE et al. Clarithromycin significantly improves interleukin-12-mediated anti-Mycobacterium avium activity and abolishes toxicity in mice. 1998 J. Infect. Dis. pmid:9728568
Gorski JC et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. 1998 Clin. Pharmacol. Ther. pmid:9728893
Cammarota G et al. One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. 1998 Aliment. Pharmacol. Ther. pmid:9678813
Barzilai A et al. Successful treatment of disseminated Mycobacterium simiae infection in AIDS patients. 1998 Scand. J. Infect. Dis. pmid:9730300
Louw JA et al. Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. 1998 Aliment. Pharmacol. Ther. pmid:9678814
Graham DY et al. Effect of H. pylori infection and CagA status on leukocyte counts and liver function tests: extra-gastric manifestations of H. pylori infection. 1998 Helicobacter pmid:9731987
Ahuja V et al. Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. 1998 Aliment. Pharmacol. Ther. pmid:9678815
Bazzoli F et al. Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. 1998 Helicobacter pmid:9731991
Grübel P and Cave DR Factors affecting solubility and penetration of clarithromycin through gastric mucus. 1998 Aliment. Pharmacol. Ther. pmid:9678818
Lanza FL et al. Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. 1998 Helicobacter pmid:9731994
Vakil N et al. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. 1998 Am. J. Gastroenterol. pmid:9732920
Chu KM et al. A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. 1998 Am. J. Gastroenterol. pmid:9732921
Horgen L et al. Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium. 1998 Antimicrob. Agents Chemother. pmid:9797242
Ouellet D et al. Pharmacokinetic interaction between ritonavir and clarithromycin. 1998 Clin. Pharmacol. Ther. pmid:9797791
Chodosh S et al. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. 1998 Clin. Infect. Dis. pmid:9798025
Craft JC et al. Clarithromycin resistance and susceptibility patterns of Mycobacterium avium strains isolated during prophylaxis for disseminated infection in patients with AIDS. 1998 Clin. Infect. Dis. pmid:9798037
Shafran SD Clarithromycin prophylaxis for disseminated Mycobacterium avium complex infection--efficacy and acquired resistance. 1998 Clin. Infect. Dis. pmid:9798038
Sakamoto M et al. [Effect of clarithromycin treatment of natural killer cell activity in patients with advanced non-small cell lung cancer]. 1998 Gan To Kagaku Ryoho pmid:9881083
Komori T et al. Effects of repeated clarithromycin administration on the pharmacokinetic properties of pindolol in rats. 1998 Biol. Pharm. Bull. pmid:9881659
Martín Mir ML et al. [Effectiveness of the eradication of Helicobacter pylori by treatment with omeprazol, amoxicillin, and clarithromycin according to dosage and administration schedule]. 1998 Gastroenterol Hepatol pmid:9882932
Gisbert JP et al. [Previous treatment with omeprazole and H. pylori: does it diminish the eradication efficacy of the "new" triple therapies of one week's duration?]. 1998 Med Clin (Barc) pmid:9887438
Koster F Paradoxical local response to therapy for Mycobacterium avium complex infection in four patients with AIDS. 1998 Clin. Infect. Dis. pmid:9597260
Baena Díez JM et al. [Treatment with omeprazole, clarithromycin and amoxicillin for one week. Their efficacy and tolerance in eradicating Helicobacter pylori in primary care]. 1998 Aten Primaria pmid:9887574
Blum AL et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. 1998 N. Engl. J. Med. pmid:9862942
Maeda S et al. Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance. 1998 Gut pmid:9863474
Dhawan VK et al. Vancomycin-resistant enterococcal colonization in nonhospitalized HIV-infected patients. 1998 West. J. Med. pmid:9830355
Alegre Herrera S et al. [Clarithromycin-carbamazepine interaction: neurological symptoms and hyponatremia]. 1998 An Med Interna pmid:9522506
Berquist WE New, improved Helicobacter pylori eradication therapy in children. 1998 J. Pediatr. Gastroenterol. Nutr. pmid:9523877
Collins LA et al. Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. 1998 Antimicrob. Agents Chemother. pmid:9527783
Gisbert JP et al. [new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic]. 1998 Med Clin (Barc) pmid:9527978
Kusuhara H et al. Evaluation of combined antibiotic-omeprazole therapies in Helicobacter pylori-infected Mongolian gerbils. 1998 J. Gastroenterol. pmid:9497215
Dubois A et al. Cure of Helicobacter pylori infection by omeprazole-clarithromycin-based therapy in non-human primates. 1998 J. Gastroenterol. pmid:9497216
Cirioni O et al. In-vitro activity of lytic peptides alone and in combination with macrolides and inhibitors of dihydrofolate reductase against Pneumocystis carinii. 1998 J. Antimicrob. Chemother. pmid:9818742
Vrioni G et al. Treatment of disseminated Mycobacterium genavense infection in a murine model with ciprofloxacin, amikacin, ethambutol, clarithromycin and rifabutin. 1998 J. Antimicrob. Chemother. pmid:9818747
Bermudez LE et al. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. 1998 Antimicrob. Agents Chemother. pmid:9449283
Martin SJ and Pendland SL Bactericidal activity and postantibiotic effect of clarithromycin and 14-hydroxyclarithromycin, alone and in combination, against Legionella pneumophila. 1998 J. Antimicrob. Chemother. pmid:9687103
Portaels F et al. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. 1998 Antimicrob. Agents Chemother. pmid:9687409
Bigard MA et al. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. 1998 Aliment. Pharmacol. Ther. pmid:9690730
Bardhan KD et al. Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication. 1998 Aliment. Pharmacol. Ther. pmid:9692693
Catalano F et al. Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9692702
Goldstein EJ et al. Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. 1998 Antimicrob. Agents Chemother. pmid:9593139
Dobrilla G et al. Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9692703
Spangler SK et al. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. 1998 Antimicrob. Agents Chemother. pmid:9593160
Harris A Current regimens for treatment of Helicobacter pylori infection. 1998 Br. Med. Bull. pmid:9604443
Doherty TM and Sher A IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. 1998 J. Immunol. pmid:9605144
Klein JO Clarithromycin and azithromycin. 1998 Pediatr. Infect. Dis. J. pmid:9655546
Howden CW and Hunt RH Treating Helicobacter pylori. 1998 Arch. Intern. Med. pmid:9827792
Bayoumi AM and Redelmeier DA Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. 1998 AIDS pmid:9727572
van der Wouden EJ et al. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. 1998 Am. J. Gastroenterol. pmid:9707042
Burman WJ et al. Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. 1998 AIDS pmid:9708410
Bergmann JS and Woods GL In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis. 1998 Int. J. Tuberc. Lung Dis. pmid:9712275
Alder JD et al. Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. 1998 Antimicrob. Agents Chemother. pmid:9736568
Améndola R et al. [Is dental plaque a normal Helicobacter pylori reservoir?]. 1998 Acta Gastroenterol. Latinoam. pmid:9713656
Takizawa H et al. Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. 1998 Eur. Respir. J. pmid:9701415
Wharton JR et al. Erythrasma treated with single-dose clarithromycin. 1998 Arch Dermatol pmid:9645634
Shimoyama T et al. [Antibiotic therapy in eradicating Helicobacter pylori infections]. 1998 Nippon Naika Gakkai Zasshi pmid:9648426
Kimura K and Sato K [Recent topics on Helicobacter pylori--Historic background and problems caused by bacteria]. 1998 Nippon Naika Gakkai Zasshi pmid:9648427
Aoyama N [Efficacy of antibiotic therapy in eradicating Helicobacter pylori]. 1998 Nippon Naika Gakkai Zasshi pmid:9648439
Sato R et al. [Problems following antibiotic therapy for eradication of Helicobacter pylori]. 1998 Nippon Naika Gakkai Zasshi pmid:9648440
Dehesa M et al. [Comparison of 2 schedules based on pantoprazole for eradication of Helicobacter pylori in patients with active duodenal ulcer]. 1998 Apr-Jun Rev Gastroenterol Mex pmid:10068730
Fennerty MB et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. 1998 Aug 10-24 Arch. Intern. Med. pmid:9701099
Mikamo H et al. Effects of long-term/low-dose clarithromycin on neutrophil count and interleukin-8 level in pyometra. 1998 Jan-Feb Chemotherapy pmid:9444409
Ziering W and McElvaine P Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis. 1998 Jan-Feb Infection pmid:9505188
Langan C et al. Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis. 1998 Jul-Aug Int. J. Clin. Pract. pmid:9796558
Habu Y et al. Triple therapy with omeprazole, amoxicillin and clarithromycin is effective against Helicobacter pylori infection in gastric ulcer patients as well as in duodenal ulcer patients. Results of a randomized controlled trial in Japan. 1998 Jul-Aug Digestion pmid:9693202
Shafran SD Prevention and treatment of disseminated Mycobacterium avium complex infection in human immunodeficiency virus-infected individuals. 1998 Jul-Sep Int. J. Infect. Dis. pmid:9831675
Venuta A et al. Azithromycin compared with clarithromycin for the treatment of streptococcal pharyngitis in children. 1998 Jun-Jul J. Int. Med. Res. pmid:9718470
Fernández Bermejo M and García Grávalos R [Ebrotidine in the eradicating treatment of H. pylori]. 1998 Jun-Jul Gastroenterol Hepatol pmid:9711019
Oberg KC Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy. 1998 Mar-Apr Pharmacotherapy pmid:9545160
Vakil N Treatment of H. pylori infection: the reality. 1998 Mar-Apr Yale J Biol Med pmid:10378357
Miehlke S et al. Comparison of omeprazole, metronidazole and clarithromycin with omeprazole/amoxicillin dual-therapy for the cure of Helicobacter pylori infection. 1998 Nov-Dec Digestion pmid:9813387
Adelglass J et al. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. 1998 Nov-Dec Pharmacotherapy pmid:9855324
Tohnai A et al. Clarithromycin suppresses proliferation of rat nasal epithelium exposed to endotoxin. 1998 Nov-Dec Am J Rhinol pmid:9883303
Mermelstein HT Clarithromycin-induced delirium in a general hospital. 1998 Nov-Dec Psychosomatics pmid:9819955
Anzueto A et al. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group. 1998 Sep-Oct Clin Ther pmid:9829441
Navuluri R and Yue S Understanding peptic ulcer disease pharmacotherapeutics. 1999 Nurse Pract pmid:10100245
Fournier S et al. Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients. 1999 Eur. J. Clin. Microbiol. Infect. Dis. pmid:10192709
Uygun A et al. Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. 1999 Am. J. Gastroenterol. pmid:10520880
Harris A The importance of clarithromycin dose in the management of H. pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. 1999 Aliment. Pharmacol. Ther. pmid:10594406
Gomollón F et al. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. 1999 Helicobacter pmid:10597390
Lugannani C and Strickland C Empiric eradication therapy or endoscopy in Helicobacter pylori-positive patients? 1999 J Fam Pract pmid:10628582
Uygun A et al. Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population. 1999 Clin Ther pmid:10509849
Sieg A et al. Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. 1999 Aliment. Pharmacol. Ther. pmid:10383519
Grimley CE et al. Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. 1999 Aliment. Pharmacol. Ther. pmid:10383520
Dubois J and St-Pierre C In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. 1999 Diagn. Microbiol. Infect. Dis. pmid:10212753
Son SW et al. The response of rosacea to eradication of Helicobacter pylori. 1999 Br. J. Dermatol. pmid:10354058
Khan AA et al. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. 1999 Int. J. Antimicrob. Agents pmid:10221415